Finanical Reports

Explore the landscape of Finanical Reports in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Finanical Reports to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Innovent's Sintilimab Plus Nogileucel (GC101) Melanoma NDA Accepted by NMPA – Backed by 57% Progression Risk Reduction in MIZAR-003
Others

Innovent’s Sintilimab Plus Nogileucel (GC101) Melanoma NDA Accepted by NMPA – Backed by 57% Progression Risk Reduction in MIZAR-003

Innovent Biologics, Inc. (HKG: 1801) announced that the marketing application for a new indication of its PD‑1 inhibitor sintilimab (brand name: Tyvyt) has been accepted by China's National Medical Products…

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Company

Hengrui Medicine’s H1 2022 Revenues Drop 23% Amid Generic Price Cuts and COVID-19 Disruptions

CompanyDigital

Ping An Good Doctor Reports 2022 Interim Results with Revenue Decline and User Growth

Company

Henlius Pharma’s 2022 Interim Revenue Jumps 103.5% on Biosimilar Sales and Licensing

Company

WuXi Biologics’ Revenues Surge 63.5% in H1 2022 on Strong CRDMO Growth

Company

EQRx Accelerates US Development of Two Chinese-Licensed Cancer Drugs

Company

Siemens Healthineers Q3 2022 Results Show Decline Amid COVID-19 Impact

Company

China Grand Pharma’s H1 2022 Revenues Up 14.1% to USD664m, R&D Spending Rises

Company

FibroGen’s Roxadustat Sales in China Rise Despite Price Cut

Show More